Karl Fengler1, Diana Heinemann1, Thomas Okon1, Karoline Röhnert1, Thomas Stiermaier1, Maximilian von Röder1, Christian Besler1, Ulrike Müller1, Robert Höllriegel1, Gerhard Schuler1, Steffen Desch2,3, Philipp Lurz4. 1. Department of Internal Medicine/Cardiology, University Heart Centre Leipzig, Strümpellstraße 39, 04289, Leipzig, Germany. 2. Department of Cardiology, Angiology and Intensive Care Medicine, University Heart Centre Luebeck, University Hospital Schleswig-Holstein, Luebeck, Germany. 3. German Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Luebeck, Luebeck, Germany. 4. Department of Internal Medicine/Cardiology, University Heart Centre Leipzig, Strümpellstraße 39, 04289, Leipzig, Germany. Philipp.Lurz@gmx.de.
Abstract
INTRODUCTION: Despite the ongoing debate on the role of renal sympathetic denervation (RSD) in the management of therapy-resistant hypertension, little is known about its possible effects on exercise blood pressure (BP), a known predictor for future cardiovascular events. We sought to evaluate the effect of RSD on exercise BP in a randomized, sham-controlled trial in patients with mild hypertension. METHODS AND RESULTS:Patients with therapy-resistant mild hypertension (defined by mean daytime systolic BP between 135 and 149 mmHg or mean daytime diastolic BP between 90 and 94 mmHg on 24-h ambulatory BP measurement) were randomized to either radiofrequency-based RSD or a sham procedure. Patients underwent cardiopulmonary exercise testing at baseline and after 6 months. Of the 71 patients randomized, data from cardiopulmonary exercise testing were available for 48 patients (22 in the RSD group, 26 in the sham group). After 6 months, patients undergoing RSD had a significantly lower systolic BP at maximum exercise workload compared to baseline (-14.2 ± 26.1 mmHg, p = 0.009). In contrast, no change was observed in the sham group (0.6 ± 22.9 mmHg, p = 0.45, p = 0.04 for between-group comparison). When analyzing patients with exaggerated baseline exercise BP only, the effect was even more pronounced (RSD vs. sham -29.5 ± 23.4 vs. 0.1 ± 25.3 mmHg, p = 0.008). CONCLUSION:Exercise systolic BP values in patients with mild therapy-resistant hypertension are reduced after RSD as compared to a sham-procedure.
RCT Entities:
INTRODUCTION: Despite the ongoing debate on the role of renal sympathetic denervation (RSD) in the management of therapy-resistant hypertension, little is known about its possible effects on exercise blood pressure (BP), a known predictor for future cardiovascular events. We sought to evaluate the effect of RSD on exercise BP in a randomized, sham-controlled trial in patients with mild hypertension. METHODS AND RESULTS:Patients with therapy-resistant mild hypertension (defined by mean daytime systolic BP between 135 and 149 mmHg or mean daytime diastolic BP between 90 and 94 mmHg on 24-h ambulatory BP measurement) were randomized to either radiofrequency-based RSD or a sham procedure. Patients underwent cardiopulmonary exercise testing at baseline and after 6 months. Of the 71 patients randomized, data from cardiopulmonary exercise testing were available for 48 patients (22 in the RSD group, 26 in the sham group). After 6 months, patients undergoing RSD had a significantly lower systolic BP at maximum exercise workload compared to baseline (-14.2 ± 26.1 mmHg, p = 0.009). In contrast, no change was observed in the sham group (0.6 ± 22.9 mmHg, p = 0.45, p = 0.04 for between-group comparison). When analyzing patients with exaggerated baseline exercise BP only, the effect was even more pronounced (RSD vs. sham -29.5 ± 23.4 vs. 0.1 ± 25.3 mmHg, p = 0.008). CONCLUSION: Exercise systolic BP values in patients with mild therapy-resistant hypertension are reduced after RSD as compared to a sham-procedure.
Authors: Peter M van Brussel; Daan W Eeftinck Schattenkerk; Linn C Dobrowolski; Robbert J de Winter; Jim A Reekers; Hein J Verberne; Liffert Vogt; Bert-Jan H van den Born Journal: Int J Cardiol Date: 2015-09-25 Impact factor: 4.164
Authors: Felix Mahfoud; Michael Böhm; Michel Azizi; Atul Pathak; Isabelle Durand Zaleski; Sebastian Ewen; Kostantinos Tsioufis; Bert Andersson; Peter J Blankestijn; Michel Burnier; Gilles Chatellier; Sameer Gafoor; Guido Grassi; Michael Joner; Sverre E Kjeldsen; Thomas Felix Lüscher; Melvin D Lobo; Chaim Lotan; Gianfranco Parati; Josep Redon; Luis Ruilope; Isabella Sudano; Christian Ukena; Evert van Leeuwen; Massimo Volpe; Stephan Windecker; Adam Witkowski; William Wijns; Thomas Zeller; Roland E Schmieder Journal: Eur Heart J Date: 2015-05-18 Impact factor: 29.983
Authors: Ján Rosa; Petr Widimský; Petr Toušek; Ondřej Petrák; Karol Čurila; Petr Waldauf; František Bednář; Tomáš Zelinka; Robert Holaj; Branislav Štrauch; Zuzana Šomlóová; Miloš Táborský; Jan Václavík; Eva Kociánová; Marian Branny; Igor Nykl; Otakar Jiravský; Jiří Widimský Journal: Hypertension Date: 2014-11-24 Impact factor: 10.190
Authors: Christian Ott; Felix Mahfoud; Axel Schmid; Tilmann Ditting; Paul A Sobotka; Roland Veelken; Aline Spies; Christian Ukena; Ulrich Laufs; Michael Uder; Michael Böhm; Roland E Schmieder Journal: J Am Coll Cardiol Date: 2013-07-10 Impact factor: 24.094
Authors: Thomas G Pickering; John E Hall; Lawrence J Appel; Bonita E Falkner; John Graves; Martha N Hill; Daniel W Jones; Theodore Kurtz; Sheldon G Sheps; Edward J Roccella Journal: Circulation Date: 2005-02-08 Impact factor: 29.690
Authors: C Tsioufis; V Papademetriou; D Tsiachris; K Dimitriadis; A Kasiakogias; A Kordalis; V Antonakis; A Kefala; C Thomopoulos; I Kallikazaros; E O-Y Lau; C Stefanadis Journal: J Hum Hypertens Date: 2014-03-13 Impact factor: 3.012
Authors: Martin Steinmetz; Dominik Nelles; Jutta Weisser-Thomas; Christian Schaefer; Georg Nickenig; Nikos Werner Journal: Clin Res Cardiol Date: 2018-04-11 Impact factor: 5.460
Authors: Anna Pisano; Luigi Francesco Iannone; Antonio Leo; Emilio Russo; Giuseppe Coppolino; Davide Bolignano Journal: Cochrane Database Syst Rev Date: 2021-11-22
Authors: Karl Fengler; Karl-Philipp Rommel; Stephan Blazek; Maximilian Von Roeder; Christian Besler; Christian Lücke; Matthias Gutberlet; Jennifer Steeden; Michael Quail; Steffen Desch; Holger Thiele; Vivek Muthurangu; Philipp Lurz Journal: Clin Res Cardiol Date: 2018-05-09 Impact factor: 5.460